[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hôpital NOVO\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":391},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,48,75,103,131,156,181,208,235,265,293,321,346,371],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644707","functional-and-aesthetic-comparison-of-surgical-nasal-reconstruction-versus-nasal-prosthesis-epithesis-after-total-or-subtotal-nasal-amputation-100644707",false,"NCT07674030","Functional and Aesthetic Comparison of Surgical Nasal Reconstruction Versus Nasal Prosthesis (Epithesis) After Total or Subtotal Nasal Amputation","Comparison of Epithesis and Surgical Nasal Reconstruction Using the SCHNOS Score","CERNAS","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Patients who have undergone total or subtotal nasal amputation (defined as loss of at least three nasal subunits, or of two subunits including the dorsum) and who have been rehabilitated either by surgical reconstruction or by nasal epithesis for more than one year\n\nExclusion Criteria:\n\n* Ongoing tumour progression or tumour recurrence\n* Non-French-speaking patients\n* Patients under legal protection measures (guardianship, legal safeguarding, limited or full legal incapacity)\n* Patients unlikely to cooperate with the study (e.g. presenting with a psychiatric disorder)","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","OBSERVATIONAL","CERNAS is a prospective, multicenter, non-interventional study comparing the functional and aesthetic outcomes of two rehabilitation strategies after total or subtotal nasal amputation: surgical reconstruction (primarily paramedian forehead flap or free flap) versus nasal epithesis (prosthesis). Patients who have undergone either rehabilitation at least one year prior to enrolment will be invited to complete the validated French version of the SCHNOS (Standardized Cosmesis and Health Nasal Outcomes Survey) questionnaire. The study aims to provide an objective, patient-reported comparison of these two options to guide future clinical decision-making.",[25,26],"Nose Cancer","Rhinectomy",[28,29,30,31,32,33,34,35],"Total rhinectomy","Nasal reconstruction","Nasal prosthesis","SCHNOS","Nasal amputation","Quality of life","Free flap","Forehead flap","NOT_YET_RECRUITING","2026-06-29",{"date":39,"type":40},"2026-07-01","ACTUAL",{"date":39,"type":21},{"date":43,"type":21},"2027-01-30",{"name":45,"class":46},"Hôpital NOVO","OTHER",4,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100645247","impact-of-parental-presence-at-the-ethics-meeting-in-neonatal-intensive-care-100645247","NCT07681518","Impact of Parental Presence at the Ethics Meeting in Neonatal Intensive Care","PaReNCo","Inclusion Criteria:\n\n* Adult parent (≥18 years)\n* Parent of a newborn for whom an ethics meeting was organized within the neonatal intensive care unit of Hôpital NOVO - Pontoise site\n* Ethics meeting organized between 01\u002F01\u002F2018 and 31\u002F12\u002F2025\n\nExclusion Criteria:\n\n* Refusal to participate in the study (refusal to complete the questionnaire and refusal to allow use of the child's medical record data)\n* Parent with a major inability to understand the study (severe cognitive impairment)\n* Parent not understanding French and therefore unable to complete the questionnaire",{"count":56,"type":21},100,"1 Day","In neonatal intensive care, physicians are sometimes confronted with decisions to withhold or withdraw life-sustaining treatment for a critically ill newborn. In France, these decisions are made by the medical team through a formal collegial (\"ethics\") meeting. Parents are not legally required to take part in this meeting, and their participation remains very rare at the national level.\n\nSince 2018, the neonatal intensive care unit of Hopital NOVO (Pontoise site) has systematically offered parents the possibility of attending the collegial ethics meeting concerning their child when withholding or withdrawal of treatment is being considered. This study aims to evaluate the value of parental presence at the ethics meeting in helping parents understand the medical decisions made for their newborn.\n\nThis is a retrospective, single-centre, non-interventional, qualitative study based on a questionnaire developed specifically for this purpose, in the absence of any validated tool. Parents of newborns for whom an ethics meeting was held between 1 January 2018 and 31 December 2025 are invited to share their experience. Two questionnaire versions are used, one for parents who attended the meeting and one for parents who did not, allowing comparison between the two situations. The questionnaire explores parents' understanding of the decision, the emotional impact of the meeting, their sense of guilt and their acceptance of the decision.\n\nMain hypothesis: parental participation in the ethics meeting promotes a better understanding of the medical decision, reduces feelings of guilt, and improves parents' long-term emotional experience.",[60],"Parental Presence in Pediatric Ethics Meetings",[62,63,64,65,66],"Neonatal intensive care","End-of-life decision-making","Ethics consultation","Collegial meeting","Parental experience","2026-06-26",{"date":69,"type":40},"2026-07-02",{"date":39,"type":21},{"date":72,"type":21},"2026-11-01",{"name":45,"class":46},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":74},"100615858","functional-and-aesthetic-outcomes-following-lower-lip-reconstruction-100615858","NCT07298070","Functional and Aesthetic Outcomes Following Lower Lip Reconstruction","REFEPLI","Inclusion Criteria:\n\n* Patient over 18 years of age.\n* Patients who underwent lower lip reconstruction after excision for skin carcinoma, operated on in Pontoise between January 1, 2014, and October 31, 2025.\n* Patients who had a post-operative follow-up consultation (± 2 months).\n* Patients who were informed and did not object to participating in the study\n\nExclusion Criteria:\n\n* Cognitive impairment preventing completion of the questionnaire.\n* Patient under legal protection (guardianship, conservatorship, or judicial protection).\n* Patient deceased.",{"count":20,"type":21},"This retrospective study, aims to evaluate the functional and aesthetic results of lower lip reconstructions, incorporating both patient experiences and the analysis of physicians and surgeons working on facial issues (plastic surgeons and dermatologists) in order to optimize future therapeutic strategies.",[85,86],"Lower Lip Tissue Loss","Cancer",[88,89,90,91,33,92,93],"Aesthetic and functional outcomes after lower lip reconstruction","Patient-reported outcome questionnaire","Post-operative","Aesthetic and functional satisfaction","Optimal patient care","Analysis of physicians and surgeons working on topics related to the face","RECRUITING","2026-06-08",{"date":97,"type":40},"2026-06-09",{"date":99,"type":40},"2026-04-21",{"date":101,"type":21},"2027-05-30",{"name":45,"class":46},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100612708","nasal-reconstruction-face-q--french-validation-of-the-nasal-reconstruction-face-q-questionnaire-for-reconstructionrehabilitation-following-nasal-skin-cancer-100612708","NCT07257094","Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction\u002FRehabilitation Following Nasal Skin Cancer","French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction\u002FRehabilitation Following Nasal Skin Cancer","PATIENTS\n\nInclusion Criteria\n\n* Age ≥ 18 years\n* Patient who has undergone excision of a cutaneous, mucocutaneous, or vestibular nasal cancer with surgical reconstruction using a flap or prosthetic rehabilitation, performed more than 4 months ago, with stable results, and less than 3 years ago\n* Patient informed of the study and not opposed to participation\n\nExclusion Criteria\n\n* Patient under anticoagulant or antiplatelet therapy Non-French-speaking patient\n* Patient under legal protection (e.g., guardianship, legal safeguard) or with limited legal capacity\n* Patient unlikely to cooperate with the study and\u002For poor anticipated compliance as judged by the investigator (including psychiatric disorders other than depressive disorder or cognitive impairment)\n* Pregnant or breastfeeding woman\n\nCONTROL\n\nInclusion Criteria\n\n* Age ≥ 65 years\n* Subject informed and not opposed to participating in the study\n* Subject who has never undergone facial trauma or surgery, and without major comorbidity, defined as follows:\n* No heart failure (moderate or severe heart failure, history of heart attack within the last 6 months);\n* No severe chronic respiratory disease (no stage III-IV COPD, no prolonged oxygen therapy);\n* No uncontrolled diabetes or associated severe complications;\n* No active immunosuppressive diseases or high-dose immunosuppressive treatment;\n* No unstable or severe facial dermatological conditions;\n* No comorbidities seriously affecting quality of life or respiratory function (at the investigator's discretion).\n\nExclusion Criteria\n\n* Non-English speaking subject\n* Subject under guardianship or legal protection, legally incompetent or with limited legal capacity\n* Subject unlikely to cooperate in the study and\u002For anticipated low cooperation by the investigator (particularly those with psychiatric disorders other than depression or cognitive disorders)\n* Pregnant or breastfeeding women",{"count":111,"type":21},346,"This study aims to validate a French version of the Nasal Reconstruction FACE-Q questionnaire for patients who have undergone nasal reconstruction or prosthetic rehabilitation after surgery for nasal skin cancer. The questionnaire evaluates appearance, quality of life, and possible side effects related to the reconstruction.\n\nThe investigators hypothesize that the validated French version will provide a reliable and standardized tool to assess patient satisfaction and health-related quality of life in this context.",[114],"Carcinoma",[116,117,26,118,119,120,121],"Basal Cell carcinoma","Squamous Cell carcinoma","Reconstructive Surgical Procedures","Prosthesis Implantation","FACE-Q","Quality of Life","2026-03-26",{"date":124,"type":40},"2026-03-31",{"date":126,"type":40},"2026-01-10",{"date":128,"type":21},"2027-07-30",{"name":45,"class":46},9,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":74},"100624646","disarticulation-septoplasty-versus-classical-way-100624646","NCT07412340","Disarticulation Septoplasty Versus Classical Way","Disarticulation Septoplasty Versus Classical Septoplasty: Retrospective Study","DSARTICULATION","Inclusion Criteria:\n\n* Patient aged 18 and over\n* Patient undergoing a new disarticulation septoplasty, or an open approach for nasal obstruction due to a deviated nasal septum, confirmed by endoscopy\n* Patient operated between 01\u002F01\u002F2023 and 31\u002F12\u002F2025\n\nExclusion Criteria:\n\nPatient undergoing surgery but with the following medical history (on the day of surgery):\n\n* Patient with septal perforations\n* Patient with previous nasal septum surgery or cosmetic rhinoplasty\n* Patient with allergic rhinitis\n* Patient with chronic sinusitis\n* Patient with concha bullosa\n* Refusal to participate",{"count":140,"type":21},40,"The objective of this study is to determine which of the two techniques (disarticulation septoplasty versus open surgery) offers the best functional results for correcting symptomatic deviations of the nasal septum.\n\nMore specifically it's about:\n\n* Compare the improvement in respiratory symptoms between the two techniques\n* Analyze and compare complication rates between the two techniques\n* Evaluate patient satisfaction with aesthetic results (including columella deviation)",[143],"Nasal Septum Deviation",[145,146,147],"Nasal septum deviation","Septoplasty","Open surgery","2026-02-17",{"date":150,"type":40},"2026-02-19",{"date":152,"type":21},"2026-01-31",{"date":154,"type":21},"2026-06-30",{"name":45,"class":46},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":166,"conditions":167,"keywords":171,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":179,"locationsCount":180},"100623272","study-of-the-association-between-sacroiliitisaxial-spondylarthritis-and-giant-cell-arteritis-polymyalgia-rheumatica-100623272","NCT07394478","Study of the Association Between Sacroiliitis\u002FAxial Spondylarthritis and Giant Cell Arteritis\u002F Polymyalgia Rheumatica","Study of the Association Between Sacroiliitis\u002FAxial Spondylarthritis and Giant Cell Arteritis\u002F Polymyalgia Rheumatica: A Case-control Observational Study","SAGE PPR","Inclusion Criteria:\n\n* Experimental group: Adult patient with spondylitis associated with GCA or PMR Control group: Adult patient with GCA or PMR\n\nExclusion Criteria:\n\n* Refusal to participate\n* Positive anti CCP",{"count":165,"type":21},10,"The purpose of the study is to recruit as many patients as possible presenting with sacroiliitis or authentic axial spondylarthritis and giant cell arteritis. The investigators will also be interested in the association of spondylarthritis and polymyalgia rheumatica given the continuum between these two pathologies. The aim is to investigate whether there is an association between giant cell arteritis and spondylarthritis or polymyalgia rheumatica and spondylarthritis.",[168,169,170],"Giant Cell Arteritis (GCA)","Spondylarthritis","Polymyalgia Rheumatica",[168,169,172],"Polymyalgia rheumatica","2026-02-03",{"date":175,"type":40},"2026-02-06",{"date":177,"type":21},"2026-02-01",{"date":154,"type":21},{"name":45,"class":46},2,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":180},"100612844","analysis-of-microbial-biofilms-in-peripheral-venous-catheters-and-their-implication-in-infectious-risk-100612844","NCT07258862","Analysis of Microbial Biofilms in Peripheral Venous Catheters and Their Implication in Infectious Risk","KTBIO","Inclusion Criteria:\n\n* Patient hospitalized in a care unit of the NOVO hospital (Pontoise site)\n* Major patient for whom a peripheral venous catheter has been in place for at least 2 days and at most 7 days, with or without signs of inflammation\n\nExclusion Criteria:\n\n* Antibiotic treatment by any route\n* Patient with viral hepatitis, or human immunodeficiency virus (HIV) or suspected epidemic and biological risk (EBR)\n* Patient unable to understand and give non-opposition to study participation\n* Patient under guardianship",{"count":189,"type":21},250,"Peripheral venous catheters (PVCs) are the most commonly used intravascular medical devices in healthcare establishments. Although essential in patient care, PVCs represent a significant risk factor for nosocomial infections, as shown by the results of the national prevalence survey. While the main pathophysiological mechanisms are known, the specific factors driving the transition from simple colonization to infection remain unclear. This project aims to identify the major factors involved in the occurrence of bacterial infections related to the colonization of peripheral venous catheters.",[192],"Catheter-Related Infections",[194,195,192,196,197,198,199],"Vascular Access Devices","Peripheral Venous Catheter","Biofilms","Molecular Biology","Next-Generation Sequencing","Scanning Electron Microscopy","2025-11-21",{"date":202,"type":40},"2025-12-02",{"date":204,"type":21},"2026-01-01",{"date":206,"type":21},"2027-03-28",{"name":45,"class":46},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":215,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":218,"phases":219,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":130},"100593024","optic-nerve-sheath-evaluation-in-giant-cell-artheritis-by-ultrasound-100593024","NCT07001059","oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound","PETRUS","Inclusion Criteria:\n\n* Patient with suspected GCA\n* Patient over 50 years\n\nExclusion Criteria:\n\n* Patient with history of GCA\n* Patient with a history of polymyalgia rheumatic (PMR) without initial PET scan\n* Patient with a history of retinal disease, demyelinating disease, or intracranial hypertension\n* Use of corticosteroids \\> 0.5mg\u002Fkg in the last 2 weeks","50 Years",{"count":217,"type":21},190,"INTERVENTIONAL",[220],"NA","The purpose of this study is to evaluate whether the measure of the optic nerve sheath is a reliable diagnostic marker for giant cell arteritis",[168],[224,225,226],"Giant Cell Arteritis","Optic nerve sheath","Ultrasound","2025-09-08",{"date":229,"type":40},"2025-09-12",{"date":231,"type":40},"2025-09-04",{"date":233,"type":21},"2028-03-31",{"name":45,"class":46},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":218,"phases":245,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":264},"100586445","phase-2-efficacy-of-direct-catheterisation-of-the-ombilical-vein-in-emergency-through-whartons-jelly-100586445","NCT06915467","Efficacy of Direct CAtheterisation of the OMbilical Vein in Emergency Through Wharton's Jelly","Efficacy of Direct CAtheterisation of the OMbilical Vein in Emergency Through Wharton's Jelly in the Delivery Room: Multicentre Study","CaDOm","Inclusion Criteria :\n\n* Full-term newborn (≥ 37 SA)\n* Newborn for whom a resuscitation decision has been taken.\n* Newborn in circulatory arrest, or in profound bradycardia \\\u003C 60 bpm, requiring an injection of adrenaline in the delivery room, the indication being established in accordance with the recommendations of the European Resuscitation Council 2021, after completion of the first stages of cardiopulmonary resuscitation, including the establishment of effective ventilation\n* Newborn beneficiary of a social security scheme or entitled person.\n\nNon-inclusion Criteria :\n\n* Newborn with known heart defects or other potentially lethal defects\n* Presence of a pre-existing access route\n* Paediatric resuscitator not trained to the UVW procedure\n* Twins born in circulatory arrest and requiring simultaneous management",{"count":244,"type":21},26,[246],"PHASE2","The aim of this study is to demonstrate, with a good level of evidence, the efficacy, safety and feasibility of placing an umbilical route through Wharton's jelly, in the context of emergency situations in the delivery room.",[249],"Newborn Morbidity",[251,252,253,254,255,256],"Cardiorespiratory arrest","Newborns","Umbilical Venous Catheter","Wharton's jelly","Neonatal resuscitation","Adrenaline injection",{"date":258,"type":40},"2025-09-09",{"date":260,"type":21},"2025-09",{"date":262,"type":21},"2027-10",{"name":45,"class":46},5,{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":218,"phases":275,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":292},"100422019","phase-3-total-post-thyroidectomy-hypocalcemia-after-preoperative-cholecalciferol-supplementation-100422019","NCT04775381","Total Post-thyroidectomy Hypocalcemia After Preoperative Cholecalciferol Supplementation","Study of Total Post-thyroidectomy Hypocalcemia After Preoperative Cholecalciferol Supplementation","CAVITHY","Inclusion Criteria:\n\n* Patient ≥ 18 years old\n* Patient shall be operated on for a total thyroidectomy in one time for any indication\n* Written informed consent (IC) obtained\n* Patients with affiliation to the social security system\n\nExclusion Criteria:\n\n• Medical history of : Thyroid or parathyroid surgery Hyperparathyroidism Granulomatosis flare-up\n\n* Hypocalcemia, hypercalcemia\u002F hypercalciuria, or symptom of Hypocalcemia, hypercalcemia\u002F hypercalciuria, not due to thyroid pathologies\n* Chronic kidney disease grade ≥4\n* Severe liver failure\n* 25OHD supplementation within last 3 months before surgery\n* Malabsorption syndrome\n* Known hypersensitivity to vitamin D\n* Medical history of calcic lithiasis\n* Pregnant women\n* Vulnerable populations (guardianship or trusteeship)\n* Allergies to one of the components of the fruit juice",{"count":274,"type":21},200,[276],"PHASE3","This prospective study evalue the inflence of pre operative vit D3 administration on post operative hypocalcemia in patients undergoing Total thyroidectomy",[279],"Hypocalcemia",[281,282,283],"Total thyroidectomy","hypocalcemia","cholecalciferol supplementation","2025-01-17",{"date":286,"type":40},"2025-01-20",{"date":288,"type":40},"2021-06-30",{"date":290,"type":21},"2026-03",{"name":45,"class":46},6,{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":301,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":218,"phases":304,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":74},"100533357","assessment-of-the-impact-of-the-return-home-of-premature-newborns-less-than-2-kilos-morbiditymortality-100533357","NCT06224764","Assessment of the Impact of the Return Home of Premature Newborns Less Than 2 Kilos Morbidity\u002FMortality","Assessment of the Impact of the Return Home of Premature Newborns With Intrauterine Growth Retardation Weighing Less Than 2 Kilos (Low Birth Weight) on Short- and Long-term Morbidity\u002FMortality","Petit-Poids","Inclusion Criteria:\n\n* Premature newborn baby (born at less than 37 days' gestation)\n* Newborn baby with IUGR (Intra-Uterine Growth Retardation)\n* Newborn baby hospitalised in the neonatology department of the NOVO hospital - Pontoise site\n* Patient born between 01\u002F01\u002F2012 and 31\u002F12\u002F2024.\n* Newborn who has left the neonatology department or the Kangaroo Unit to return home weighing less than 2 kg.\n* Newborn beneficiary of a social security scheme or entitled person.\n\nExclusion Criteria:\n\n* Newborn transferred to another hospital before discharge.\n* Refusal by one of the parents.\n* Parent does not speak or understand French.","1 Month","11 Years",{"count":140,"type":21},[220],"The aim of this study is to evaluate the impact of discharge from hospital with a weight of less than 2 kilos.\n\nTo do this, the investigator will look at the short-term and long-term outcome of newborns weighing less than 2 kilos who were discharged from the neonatology department at the NOVO hospital between 2012 and 2024.",[307],"Premature Birth",[309,310,311,312],"Prematurity","Weight at discharge","Morbi-mortality","Neonatology","2025-01-02",{"date":315,"type":40},"2025-01-03",{"date":317,"type":40},"2024-02-21",{"date":319,"type":21},"2025-11",{"name":45,"class":46},{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":330,"conditions":331,"keywords":333,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":47},"100554069","how-many-patients-suffering-major-trauma-would-be-eligible-for-a-pre-hospital-transfusion-100554069","NCT06494293","How Many Patients Suffering Major Trauma Would be Eligible for a Pre-hospital Transfusion","How Many Patients Suffering Major Trauma Would be Eligible for a Pre-hospital Transfusion: A Multicentre Retrospective Study.","TRAP","Inclusion Criteria :\n\n* Patients over 18\n* Taken care of by a MICU team from participating centres\n* Victims of major trauma requiring transport to an emergency\u002Frecovery unit or declared dead during care\n* Informed and did not object to the collection of his data for research purposes during his lifetime\n\nExclusion Criteria :\n\n* Traumatological reason for departure not confirmed in the emergency medical services report\n* Patient care of by the MICU for secondary transport (transport from one hospital to another)\n* Patient died without resuscitation by a professional\n* Patient with manifest isolated closed head injury\n* Patient deprived of civil rights",{"count":274,"type":21},"The aim of the study is to measure the number of patients being cared for by a medical team for major trauma who could benefit from a transfusion labile blood products and thus provide a scientific argument in favour of supplying labile blood products to pre-hospital",[332],"Trauma Injury",[334,335,336,337],"Major trauma","Mobile Intensive Care Unit (MCIU)","Out of hospital emergency care","Blood transfusion","2024-12-30",{"date":340,"type":40},"2024-12-31",{"date":342,"type":21},"2025-04",{"date":344,"type":21},"2025-05",{"name":45,"class":46},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":370,"locationsCount":74},"100479516","recognition-of-a-cardiac-arrest-within-the-ems-100479516","NCT05523999","Recognition of a Cardiac Arrest Within the EMS","Evaluation of the Optimal Time of Recognition of a Cardiac Arrest Within the EMS 95","ACR90","Inclusion Criteria :\n\n\\- Any call resulting in the detection of a cardiac arrest during ARM regulation: calls to 15 and calls transmitted by 18\n\nExclusion Criteria :\n\n* Traumatic context\n* Call involving cardiac arrest already identified as such by the caller or 18\n* Call with criteria of proven death\n* The caller does not speak French, the linguistic elements noted are not usable.",{"count":355,"type":21},50,"This study aims to evaluate the average time taken by the Medical Regulation Assistants (MRA) to detect a cardiac arrest during the call to the EMS as well as the factors influencing this delay.\n\nIts main objective is to evaluate the delay, in seconds, between the call being picked up and the recognition of a cardiac arrest by the medical regulation assistant at the EMS 95",[358],"Cardiac Arrest",[360,361,362,363,364,365],"cardiorespiratory arrest (CRA)","Medical Regulation Assistant (MRA)","EMS","External Cardiac Massage","External Automated Defibrillator","90 seconds",{"date":340,"type":40},{"date":368,"type":40},"2024-06-03",{"date":342,"type":21},{"name":45,"class":46},{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":381,"conditions":382,"keywords":383,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":390,"locationsCount":74},"100558456","retrospective-assessment-of-referral-of-a-major-trauma-patient-100558456","NCT06551350","Retrospective Assessment of Referral of a Major Trauma Patient","Retrospective Assessment of Referral of a Major Trauma Patient in Val-d'Oise","SAMU-TRAUMAS","Inclusion Criteria :\n\n* Between the 1st January 2023 and the 31th December 2023\n* Regulated by SAMU 95 with suspected major trauma\n* Sending an MCIU\n* At least 1 Vittel criterion\\*\n\nExclusion Criteria :\n\n* Death on site\n* Care by an MICU team outside the 95\n* Minor patients and legal protection\n* Transport refusals\n\n  * Vittel criterion :\n\n    • Physiological variables : Glasgow score \\\u003C 13 Systolic blood pressure \\\u003C 90 mmHg O2 saturation \\\u003C 90%\n\n    • Elements of kinetics : Ejection from a vehicle Other passenger killed in the same vehicle Fall \\> 6 metres Victim thrown or crushed Overall assessment (deformation of the vehicle, estimated speed, absence of helmet, absence of seatbelt) Blast\n\n    • Anatomical lesions : Penetrating trauma to the head, neck, thorax, abdomen, pelvis, arm or thigh Flail chest Severe burn, smoke inhalation Pelvic fracture Suspected spinal cord injury Amputation of wrist, ankle or above Acute limb ischaemia\n\n    • Pre-hospital resuscitation : Assisted ventilation Filling \\> 1000 ml with colloids Catecholamines Inflated shock-proof trousers\n\n    • Medical context (to be assessed) : Age \\> 65 Cardiac or coronary insufficiency Respiratory insufficiency Pregnancy (2nd and 3rd trimesters) Blood crase disorders",{"count":380,"type":21},461,"The aim of this study is to find out whether major trauma patients from the Val d'Oise are referred to the appropriate trauma centre for their care and to assess the quality of triage within the Val d'Oise department.",[332],[334,335],"2024-12-04",{"date":386,"type":40},"2024-12-05",{"date":388,"type":40},"2024-10-18",{"date":344,"type":21},{"name":45,"class":46},""]